Physician profile
Elkin Estrada
NPI 1811995509
$10,593.78
in general payments reported to CMS, 2019-2025
33 companies · $2,475 in 2025
The $2,475 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,644 · 2020: $784 · 2021: $1,311 · 2022: $1,113 · 2023: $1,379 · 2024: $1,888 · 2025: $2,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,378 · Education: $364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,377.80 |
| Education | $364.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,580.87 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $890.71 | 2019-2025 | Tavneos, Aranesp, Parsabiv |
| Vifor Pharma, INC. | $862.60 | 2019-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $843.19 | 2019-2025 | Jynarque, Voyxact |
| Alexion Pharmaceuticals, INC. | $580.28 | 2019-2025 | Ultomiris, Soliris |
| Bayer Healthcare Pharmaceuticals INC. | $543.19 | 2021-2025 | |
| Glaxosmithkline, LLC. | $470.18 | 2021-2025 | Benlysta |
| Calliditas Therapeutics US INC. | $453.64 | 2022-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $446.28 | 2019-2025 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $427.62 | 2020-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $397.71 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Aurinia Pharma U.S., INC. | $390.04 | 2021-2025 | Lupkynis |
| Akebia Therapeutics INC | $378.55 | 2019-2025 | Vafseo, Auryxia |
| Horizon Therapeutics Plc | $353.94 | 2019-2021 | |
| Travere Therapeutics, INC. | $346.92 | 2022-2025 | Filspari |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $234.18 | 2019-2021 | |
| Ardelyx, INC. | $203.81 | 2023-2025 | Ibsrela |
| Daiichi Sankyo INC. | $202.35 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $200.79 | 2020-2025 | Terlivaz |
| Novo Nordisk INC | $188.14 | 2025 | Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $141.11 | 2022-2025 | |
| Lexicon Pharmaceuticals, INC. | $104.70 | 2023-2024 | Inpefa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $93.66 | 2019-2025 | |
| Ultragenyx Pharmaceutical INC. | $40.79 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $40.31 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.45 | 2020-2021 | |
| Shire North American Group INC | $32.41 | 2019 | |
| Alnylam Pharmaceuticals INC. | $29.57 | 2024 | Onpattro |
| Regeneron Healthcare Solutions, INC. | $23.22 | 2019 | |
| Mallinckrodt Enterprises LLC | $21.76 | 2019 | |
| Apellis Pharmaceuticals, INC. | $19.54 | 2025 | Empaveli |
| Strongbridge US INC. | $13.27 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elkin Estrada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.